Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXOTCMKTS:IPSEYNASDAQ:LNTHNASDAQ:QDEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$20.35-0.1%$18.91$14.40▼$47.00$1.35B1.39895,300 shs477,438 shsIPSEYIpsen$29.20+1.1%$28.43$25.11▼$34.06$9.79B0.545,130 shs533 shsLNTHLantheus$73.86-1.2%$94.56$73.11▼$126.89$5.11B0.23987,972 shs671,503 shsQDELQuidelOrtho$29.74-1.5%$30.54$23.77▼$49.45$2.01B0.131.07 million shs1.38 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics-0.10%-0.49%+4.73%-9.39%-46.59%IPSEYIpsen+1.11%+2.28%+8.53%+3.07%-12.05%LNTHLantheus-1.19%-9.08%-27.02%-5.59%-9.20%QDELQuidelOrtho-1.46%-11.12%+15.11%-26.50%-30.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics1.9641 of 5 stars4.50.00.00.03.70.00.0IPSEYIpsenN/AN/AN/AN/AN/AN/AN/AN/ALNTHLantheus4.4413 of 5 stars3.51.00.04.23.92.51.9QDELQuidelOrtho4.4814 of 5 stars3.22.00.03.84.11.72.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.90Moderate Buy$53.90164.86% UpsideIPSEYIpsen 3.00BuyN/AN/ALNTHLantheus 3.00Buy$132.6779.62% UpsideQDELQuidelOrtho 2.43Hold$44.3349.07% UpsideCurrent Analyst Ratings BreakdownLatest IPSEY, LNTH, QDEL, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/8/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $117.005/8/2025QDELQuidelOrthoUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$45.00 ➝ $29.005/8/2025QDELQuidelOrthoJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$44.005/6/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/28/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$64.004/21/2025QDELQuidelOrthoJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$38.00 ➝ $25.004/2/2025IPSEYIpsenDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/21/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $122.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.56M178.72N/AN/A$9.08 per share2.24IPSEYIpsen$3.87B2.53N/AN/AN/A∞LNTHLantheus$1.54B3.33$6.17 per share11.98$11.91 per share6.20QDELQuidelOrtho$2.76B0.73$23.05 per share1.29$44.75 per share0.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$141.43M-$2.70N/AN/AN/A-1,544.32%-19.75%-18.86%N/AIPSEYIpsen$374.34MN/A0.0010.14N/AN/AN/AN/A7/31/2025 (Estimated)LNTHLantheus$326.66M$3.5212.2911.71N/A28.57%44.29%23.52%7/30/2025 (Estimated)QDELQuidelOrtho-$2.03B-$4.97N/A9.26N/A-72.84%3.78%1.80%7/30/2025 (Estimated)Latest IPSEY, LNTH, QDEL, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 million5/7/2025Q1 2025QDELQuidelOrtho$0.61$0.74+$0.13-$0.19$694.97 million$692.80 million2/27/2025Q4 2024CLDXCelldex Therapeutics-$0.73-$0.71+$0.02-$0.71$1.25 million$1.18 million2/27/2025Q4 2024LNTHLantheus$1.57$1.34-$0.23-$0.17$376.61 million$391.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AIPSEYIpsen$0.210.72%N/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AQDELQuidelOrthoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A24.2724.27IPSEYIpsenN/A1.140.98LNTHLantheusN/A1.651.56QDELQuidelOrtho0.711.220.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AIPSEYIpsenN/ALNTHLantheus99.06%QDELQuidelOrtho99.00%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics3.80%IPSEYIpsenN/ALNTHLantheus1.50%QDELQuidelOrtho0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.82 millionOptionableIPSEYIpsen5,325335.26 millionN/ANot OptionableLNTHLantheus70069.19 million68.48 millionOptionableQDELQuidelOrtho7,00067.63 million66.58 millionOptionableIPSEY, LNTH, QDEL, and CLDX HeadlinesRecent News About These CompaniesQuidelOrtho to Participate in Upcoming Investor ConferencesMay 22 at 4:30 PM | businesswire.com70,000 Shares in QuidelOrtho Co. (NASDAQ:QDEL) Purchased by Paradigm Capital Management Inc. NYMay 22 at 8:00 AM | marketbeat.comPoint72 Asset Management L.P. Has $4.18 Million Stock Position in QuidelOrtho Co. (NASDAQ:QDEL)May 22 at 4:42 AM | marketbeat.comAmeriprise Financial Inc. Has $10.84 Million Holdings in QuidelOrtho Co. (NASDAQ:QDEL)May 22 at 3:18 AM | marketbeat.comReasons to Retain QuidelOrtho Stock in Your Portfolio for NowMay 21 at 10:46 AM | zacks.comSoleus Capital Management L.P. Lowers Holdings in QuidelOrtho Co. (NASDAQ:QDEL)May 21 at 8:07 AM | marketbeat.comDeutsche Bank AG Sells 153,431 Shares of QuidelOrtho Co. (NASDAQ:QDEL)May 21 at 3:52 AM | marketbeat.comStanley Capital Management LLC Buys New Holdings in QuidelOrtho Co. (NASDAQ:QDEL)May 20, 2025 | marketbeat.comSystematic Financial Management LP Boosts Stock Position in QuidelOrtho Co. (NASDAQ:QDEL)May 20, 2025 | marketbeat.comQuidelOrtho Corp (QDEL) Stock Price Down 3.32% on May 19May 19, 2025 | gurufocus.comNorthRock Partners LLC Buys New Holdings in QuidelOrtho Co. (NASDAQ:QDEL)May 17, 2025 | marketbeat.comParkman Healthcare Partners LLC Acquires 100,415 Shares of QuidelOrtho Co. (NASDAQ:QDEL)May 16, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL)May 16, 2025 | marketbeat.comWhy QuidelOrtho (QDEL) is a Top Growth Stock for the Long-TermMay 15, 2025 | zacks.comGotham Asset Management LLC Grows Stock Position in QuidelOrtho Co. (NASDAQ:QDEL)May 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Boosts Holdings in QuidelOrtho Co. (NASDAQ:QDEL)May 14, 2025 | marketbeat.comQuidelOrtho (QDEL) Faces Tariff Impact, Maintains 2025 OutlookMay 13, 2025 | gurufocus.comQuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)May 12, 2025 | seekingalpha.comEngine Capital Management LP Invests $14.77 Million in QuidelOrtho Co. (NASDAQ:QDEL)May 11, 2025 | marketbeat.comBalyasny Asset Management L.P. Invests $14.25 Million in QuidelOrtho Co. (NASDAQ:QDEL)May 11, 2025 | marketbeat.comClearline Capital LP Cuts Stock Position in QuidelOrtho Co. (NASDAQ:QDEL)May 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreBy Sam Quirke | May 14, 2025View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreIPSEY, LNTH, QDEL, and CLDX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$20.35 -0.02 (-0.10%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$20.34 -0.01 (-0.02%) As of 05/23/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Ipsen OTCMKTS:IPSEY$29.20 +0.32 (+1.11%) As of 05/23/2025 03:58 PM EasternIpsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.Lantheus NASDAQ:LNTH$73.86 -0.89 (-1.19%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$74.75 +0.89 (+1.20%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.QuidelOrtho NASDAQ:QDEL$29.74 -0.44 (-1.46%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$29.46 -0.28 (-0.94%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
